U.S. markets closed

Precipio, Inc. (PRPO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.0700-0.0100 (-0.93%)
At close: 04:00PM EDT
1.1000 +0.03 (+2.80%)
After hours: 07:52PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close1.0800
Bid1.0700 x 1300
Ask1.0900 x 900
Day's Range1.0500 - 1.0900
52 Week Range0.9100 - 4.6500
Avg. Volume268,930
Market Cap24.298M
Beta (5Y Monthly)2.28
PE Ratio (TTM)N/A
EPS (TTM)-0.5230
Earnings DateMay 30, 2022 - Jun 03, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for PRPO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Precipio, Inc.
    Analyst Report: Quest Diagnostics, Inc.Quest Diagnostics is a leading global provider of clinical diagnostic services that help to identify and treat disease and improve healthcare management. The company incorporated in Delaware in 1990; its predecessor companies date back to 1967. Quest is based in Secaucus, New Jersey and employs roughly 49,000 people; the stock is a component of the S&P 500.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Simply Wall St.

    When Will Precipio, Inc. (NASDAQ:PRPO) Breakeven?

    We feel now is a pretty good time to analyse Precipio, Inc.'s ( NASDAQ:PRPO ) business as it appears the company may be...

  • GlobeNewswire

    Precipio Signs First IV-Cell Customer Agreement

    Laboratory operating both HemeScreen® & IV-Cell® demonstrates significant cross-sell potentialNEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that American Oncology Network (AON) of Fort Myers, Florida, has completed its validation of Precipio’s proprietary IV-Cell® culture media, and will adopt the product for use in its clinical cytogenetics laboratory. The adoption of IV-Cell by industry leader AON demonstr

  • GlobeNewswire

    Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference

    NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen, its novel diagnostic technology platform, at the Executive War College, organized by publication Dark Daily, the premier laboratory conference, held April 26th through 28th in New Orleans. Gathering for the first time in person after two years, laboratory executives will meet at the conference to shar